{"id":470059,"date":"2021-04-01T16:03:27","date_gmt":"2021-04-01T20:03:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470059"},"modified":"2021-04-01T16:03:27","modified_gmt":"2021-04-01T20:03:27","slug":"cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/","title":{"rendered":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., April  01, 2021  (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2021 it granted stock options to purchase an aggregate of 163,700 shares of common stock to three new employees, whose employment commenced in March 2021, as a material inducement to their employment. These grants include the grant of stock options to purchase 150,000 shares of common stock to the Company\u2019s new chief commercial officer, Andrew Callos. The grant was previously approved by the Compensation and Talent Committee of Cytokinetics\u2019 Board of Directors under the company\u2019s Amended and Restated 2004 Equity Incentive Plan.<\/p>\n<p align=\"justify\">The stock options that were granted, including the stock options granted to Mr. Callos, are subject to an exercise price of $23.26 per share, which is equal to the closing price of the Company\u2019s common stock on March 31, 2021, and will vest over 4 years, with 1\/4<sup>th<\/sup> of the shares underlying the employee\u2019s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1\/48<sup>th<\/sup> of the shares underlying each employee\u2019s option over the subsequent 36 months, subject to the new employee\u2019s continued service with the Company. Each stock option has a 10-year term and is subject to the terms and conditions of the Company&#8217;s Amended and Restated 2004 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.\u00a0\u00a0<\/p>\n<p align=\"justify\">The options were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>\n        <strong>About Cytokinetics<\/strong>\n      <\/p>\n<p align=\"justify\">Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and\/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing for regulatory interactions for <em>omecamtiv mecarbil<\/em>, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of <em>omecamtiv mecarbil<\/em>. Cytokinetics is also developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics is also developing <em>reldesemtiv<\/em>, a fast skeletal muscle troponin activator for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is preparing for the potential advancement of <em>reldesemtiv<\/em> to a Phase 3 clinical trial in ALS. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.<\/p>\n<p>For additional information about\u00a0Cytokinetics, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OFg-hpvehjLbILpNKsxCdM9eIXzItI9YnJkf1Ou7gzEpQfl_fzApofXXdZJZHGTiSpnIKdmb6jepfTqYt291c4AR1cSIIn1GNiTof7pOA88=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cytokinetics.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P5UR15-7lVm-T7srJrmluVzOdUDCMTfwSLPmLElsHRMaQzno_oti0viyJekppl4D2visfr1PGCTYbtZQNaAstg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mMW7qKGtHbSTkfnc5z41mTd_beQTNYO3VLlm9-mUPVMZUawDwBLmr3IkIzVgzzPCf7dV2ecQ1TRADJapKA6DdkCmb7bXaHq1ayV7odSpK9A=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=utTmhDJ921gwxCxeWfA8ItYnsuJg8XFMPlcw75L7Gzd_eNZrpXiPTGDrcn2w_i-NnYATyH5j_KFp4FEhtwfp8ru7AOA5BHQ5xcpGdvtLl9Y=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C6keyJ9hBT45Vuwo37aPQWK-wAj1PyGooiwtHOB5ARcNuP0YGHRw_5IZNkiGRfvCjJWSSxbPQYwbZMwhRytWIJAJsu35oMhQd17UV8o8q3W_8DS7yNIW44wBkMmu7GJU\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the &#8220;Act&#8221;).\u00a0Cytokinetics\u00a0disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act&#8217;s\u00a0Safe Harbor\u00a0for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to\u00a0Cytokinetics&#8217;\u00a0and its partners&#8217; research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management&#8217;s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to\u00a0Cytokinetics&#8217;\u00a0business outlined in\u00a0Cytokinetics&#8217;\u00a0filings with the\u00a0Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and\u00a0Cytokinetics&#8217;\u00a0actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that\u00a0Cytokinetics\u00a0makes in this press release speak only as of the date of this press release.\u00a0Cytokinetics\u00a0assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p align=\"left\">Contact:<br \/>Cytokinetics<br \/>Diane Weiser<br \/>Senior Vice President, Corporate Communications, Investor Relations<br \/>(415) 290-7757<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/45f92444-c65a-4b98-b037-8e3593a6fb2b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., April 01, 2021 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2021 it granted stock options to purchase an aggregate of 163,700 shares of common stock to three new employees, whose employment commenced in March 2021, as a material inducement to their employment. These grants include the grant of stock options to purchase 150,000 shares of common stock to the Company\u2019s new chief commercial officer, Andrew Callos. The grant was previously approved by the Compensation and Talent Committee of Cytokinetics\u2019 Board of Directors under the company\u2019s Amended and Restated 2004 Equity Incentive Plan. The stock options that were granted, including the stock options granted to Mr. Callos, are subject to an &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-470059","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., April 01, 2021 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2021 it granted stock options to purchase an aggregate of 163,700 shares of common stock to three new employees, whose employment commenced in March 2021, as a material inducement to their employment. These grants include the grant of stock options to purchase 150,000 shares of common stock to the Company\u2019s new chief commercial officer, Andrew Callos. The grant was previously approved by the Compensation and Talent Committee of Cytokinetics\u2019 Board of Directors under the company\u2019s Amended and Restated 2004 Equity Incentive Plan. The stock options that were granted, including the stock options granted to Mr. Callos, are subject to an &hellip; Continue reading &quot;Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T20:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2021-04-01T20:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/\"},\"wordCount\":692,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/\",\"name\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM=\",\"datePublished\":\"2021-04-01T20:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., April 01, 2021 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2021 it granted stock options to purchase an aggregate of 163,700 shares of common stock to three new employees, whose employment commenced in March 2021, as a material inducement to their employment. These grants include the grant of stock options to purchase 150,000 shares of common stock to the Company\u2019s new chief commercial officer, Andrew Callos. The grant was previously approved by the Compensation and Talent Committee of Cytokinetics\u2019 Board of Directors under the company\u2019s Amended and Restated 2004 Equity Incentive Plan. The stock options that were granted, including the stock options granted to Mr. Callos, are subject to an &hellip; Continue reading \"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T20:03:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2021-04-01T20:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/"},"wordCount":692,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/","name":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM=","datePublished":"2021-04-01T20:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMDM3OCM0MTAyNzY1IzIwMDUxMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=470059"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470059\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=470059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=470059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=470059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}